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ABSTRACT

Thioltransferase and derivatives thereof are provided. Meth
ods of treating or preventing cataract formation comprising
administering thioltransferase or a derivative thereof are also
provided. Thioltransferase or derivatives thereof are also
useful for treating or preventing diseaseS resulting from or
asSociated with oxidative StreSS. Human lens thioltransferase

and a DNA sequence encoding the same are also provided.
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GCCATGGCTC AAGAGTTTGT GAACTGCAAA ATCCAGCCTG GGAAGGTGGT AGTTTTCATC

MetAlaG linGlu PheVa

lASnCySLys IleGlnProG lyLysVal Va

lVal Phelle

(60)
(19)

AAGCCCACCT GCCCCTTCTG CGTAAAGACA CAGGAGCTCC TCAGCCAATT GCCCTTCAAA
Llys ProThrC ysProPheCy sVallys Thr GlnGlul eul euSerGlnLe uProPhelys

(120)

GAAGGGCTTC TGGAATTTGT CGATATTACA GCCACCAGTG ACACCAACGA GATTCAAGAT
GluglyLieul euGluPheVa lAspilleThr Ala Thir SerA spThrAsnGl ulleOlin Asp

(180)

(39)
(59)

TATCTGCAAC AGCTCACAGG AGCCAGAACG GTACCTCGGG TCTTTATCGG TAAAGAGTGT (240)
TyrLeuGling linLeuThrCl yAlaArgThr Val ProArgV at PhelleGl yLysGluCys (79)

ATAGGTGGAT GCACTGATCT AGAAAGTATG CACAAGAGAG GGGAGCTCTT GACCCGCCTG (3 OO)
IleGlyGlyC ys ThrAsple uGluSerMet His Lieu Arg(G lyGlul eule uThrArgLieu (99)
CAGCAAATTG GAGCTCTGAA ATA ATTACAG CAGAGCAGAC CCAAGCTGAT AGCTCCCTTG (360)
(106)
GlnGlinIleG lyAlaLieuLy S
AGAGCTGGAT GGCAGTGCAG ATAATGACAG CGCTTCCTGG TGGATGGATG CCGGGCTACC

(420)

TTCACTCAGC TGCAACTACT GTTTACTTAA AAATTCTGAA ATGTGTTAAC CCAAATAATT (480)
GGGGGGAGTG GGTTTTGGGG GACAAAACAG ATTTTTCTTC TG

F.G. 1

(520)
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1
COMPOSITION AND METHOD FOR THE
PREVENTION AND TREATMENT OF
OXIDATIVE DAMAGE IN OCULAR TISSUES
GOVERNMENT RIGHTS

This invention was made in part with government Support
under grant number R01-10595 awarded by the National
Eye Institute. The government has certain rights in the
invention.
1O

BACKGROUND OF THE INVENTION

In one aspect, the present invention relates generally to
the field of ophthalmology and, more particularly, to com
positions and methods for the prevention or treatment of eye
diseases, Such as cataracts. In another aspect, the present
invention relates to the prevention or treatment of diseases
caused by oxidative StreSS or having oxidative StreSS as a

15

component.

The lens consists of concentric layers of fiber cells with
hexagonal croSS Sections packed together to create a very
regular array of fiber cells which stretch from anterior to
posterior pole. The lens fiber cells lose all intracellular
organelles that could contribute to light Scattering during the
process of differentiation and the ctyoplasmic protein con
centration increases markedly. Lens transparency is the
result of a uniform Structure of the cells cytoplasm, which
exists in an ordered, homogeneous State.
Approximately 35% to 60% of the total mass of the lens
consists of Structural proteins with the remainder being
water. These cells contain primarily the crystallin proteins.
When these proteins are modified by oxidative stress, con
formational changes and aggregates result which, in turn,
disrupt the protein lattice and damage the cell. This cellular
damage leads to a further disruption of the regular layers of
cells, resulting in opacities, or cataracts, of the lens.
More than 90% of the total lens protein consists of alpha,

25

asSociated with oxidative StreSS.

Antioxidant therapy has been proposed to ameliorate the
destructive effects of oxidation resulting in the formation of

cataracts (American J. of Clinical Nutrition, vol. 53,
pp.335S-345S (1991) and pp.352S-355S (1991)). Such
proposed therapy has included the Systemic administration
of vitamins C and E and beta carotene. The use of phenolic
antioxidants, Such as probucol, to inhibit the development of
35

40

45

819–26 (1990)). Protein-glutathione (PSSG) and protein
cysteine (PSSC) are the products of such protein modifica
tion that have been implicated as a direct precursor of
50

(Cui et al., “The effect and recovery of long term HO

exposure on lens morphology and biochemistry,” Exp. Eye

Res., vol. 57, 157-67 (1993)).
In unstressed normal cells, the concentration of

55

S-thiolated proteins is very low and the dethiolation rate,
i.e., the breakdown of mixed disulfides by reduction of
disulfide bonds, may be sufficient to maintain the fully
reduced protein Status. Such a Situation has been observed in
the HO pre-exposed lenses after the oxidant was removed

60

changes of glutathione and protein-thiol mixed disulfides in
H2O induced cataract in rat lenses: distributions and effect
implies that the maintenance of the redox Status of the
Sulfhydryl groups of the protein is vital to the physiological

lecular disulfide thereof for the treatment of cataract. Alpha
lipoic acid is disclosed as an anticataract agent in Maitra et
al., “Alpha-Lipoic Acid Prevents Buthionine Sulfoximine

cal Biology and Medicine, vol. 18, pp. 823–829 (1995). The

use of phase Separation inhibitorS is proposed in U.S. Pat.
Cataracts are the leading cause of blindness in humans,
with more than one million cataract extractions performed
each year in the United States and with an estimated 5 to 10
million people becoming visually disabled each year due to
cataracts. Cataracts in animals also pose a Significant vet
erinary problem. Currently, no accepted nonSurgical therapy
for the prevention and treatment of cataracts exists.
Although various drugs have been proposed for use in the
treatment and prevention of cataracts, it would be desirable
to avoid potential adverse effects, Such as chemical related
toxicity, of Such compounds.
SUMMARY OF THE INVENTION

The present invention is directed to compositions and
methods for preventing or delaying the onset of cataracts
and for treating or inhibiting the progression of cataracts in
animals through the administration of thioltransferase

from the culture medium (Cui et al., Exp. Eye Res., vol. 57,
157-67 (1993); Lou et al., “Further studies on the dynamic

of aging,” Curr. Eye Res., vol. 14, 951-58 (1995)). This

Application No. WO 94/03167 discloses the use of N-(3mercapto-2,2-dimethylpropanoyl)cysteine and the intramo

No. 5,401,880 to Clark et al.

protein-protein disulfides (PSSP) in rat lenses cultured with

HO. These changes ultimately lead to protein insolubility,
loSS of transparency of the lens tissue, and cataract formation

al. The use of N,N'-bis(mercaptoacetyl)hydrazine deriva

Induced Cataract Formation in Newborn Rats.” Free Radi

oxidative damage (Lou et al., “The role of protein thiol
mixed disulfides in cataractogenesis,” Exp. Eye ReS., Vol. 50,

cataracts, is disclosed in U.S. Pat. No. 5,061,734 to Mao et

tives as anticataract agents is disclosed in U.S. Pat. Nos.
5,686,450 and 5,688,828, both to Hellberg et al. PCT

beta, and gamma crystallins (in excess of 300 mg/ml) in the

lens cell cytoplasm. Crystallins are proteins containing
numerous Sulfhydryl groups, making them Susceptible to
oxidative damage. Protein S-thiolation, the formation of
mixed disulfides between non-protein thiols and protein
Sulfhydryl groups in the lens, is an early event under

2
function of the lens, a tissue abundant in Sulfhydryl groups
and extremely Vulnerable to oxidative damage.
The redox state of the cell is maintained by many
reductants, such as glutathione (GSH), NADPH, ascorbate,
and tocopherol (Spector, “The lens and oxidative stress,” in
Oxidative Stress, Oxidants, and Antioxidants (Sies, Ed.) pp.
529-58, Academic Press: London (1991)). Among these
reductants, GSH has a significant role in maintaining the
reduced condition of the cell. Traditionally, GSH with
glutathione reductase has been viewed as the System respon
Sible for maintaining and regenerating the protein thiol
groups that are Susceptible to oxidation. Reduced GSH and
other thiol containing molecules act, at least indirectly, as
oxygen free radical Scavengers, due to their easily oxidizable
Sulfhydryl groups and hence act as Sulfhydryl antioxidants in
normal lenses. Glutathione reductase regenerates GSH from
its disulfide oxidized form (GSSG) and acts as a sulfhydryl
buffering System, continually controlling the Sulfhydryl/
disulfide balance in the cell. GSH exists in great excess of
its GSSG oxidized counterpart in the cellular cytoplasm,
thus creating a Strong potential for cytosolic proteins to exist
in a Sulfhydryl-reduced, non-crosslinked State. Deficiencies
of GSH have been observed in cataractous lenses (Biochim
et Biophy's Acta, vol. 1138, 11-19 (1992)). This deficiency
leads to a reduced ability of the cell to repair damage

65

(glutaredoxin) or derivatives thereof. In another aspect, the

present invention is directed to the prevention and treatment
of oxidative StreSS or damage and disease States associated

US 6,379,664 B1
4
ably further comprises a pharmaceutically acceptable carrier
in accordance with formulation techniques known to those

3
therewith through the administration of thioltransferase or
derivatives thereof. In one embodiment the animal may be
a mammal. When the animal is a mammal, it may be a

skilled in the art.

human.

The present invention is based on our discovery of the
presence of thioltransferase in the lens and other ocular
tissues, including the cornea cells, iris, and retina, all Vul
nerable to oxidative damage. Thioltransferase has been
found by us to be an intrinsic repair System capable of
dethiolating mixed disulfides associated with cataract ini
tiation and formation, and thus is capable of repairing
damaged proteins and nonprotein thiols by restoring them to
their respective normally reduced States. It has also been
found by us that thioltransferase can dethiolate enzymes
damaged by thiolation, thus reactivating the catalytic func
tion of the enzymes. Because thioltransferase in an endog

AS used herein, the term “pharmaceutically acceptable
carrier encompasses any of the Standard pharmaceutically
acceptable carriers known to those skilled in the art.
Examples of Such Standard carriers include, but are not

limited to, phosphate buffered saline (PBS) solution, water,

15

enous biomolecule, it will cause no adverse effects due to

chemical related toxicity.

thioltransferases, and So forth. Other thioltransferases are

BRIEF DESCRIPTION OF THE DRAWINGS

The detailed description of the invention may be best
understood when read in reference to the accompanying
drawings wherein:
FIG. 1 shows the nucleotide and the deduced amino acid

25

Sequence of the coding region of the human lens thioltrans
FIG. 2 shows the alignment of the deduced amino acid
Sequence of thioltransferases,
FIGS. 3A and 3B show the time dependent dethiolation in
the presence and absence of HLTT;

thioltransferase; and

40

45

binant human lens thioltransferase.

Thioltransferase acts as a repair enzyme under oxidative
StreSS to prevent lens protein aggregation by protecting thiol
groups from oxidation and restoring thiolated proteins to
their normal reduced State by cleaving protein-thiol mixed
disulfides, thus preventing protein-protein disulfide
crosslinking. Thioltransferase also acts as a primary anti
oxidant by protecting the lens from oxidation by its ability
to regenerate ascorbic acid, an important free radical Scav

50

55

60

enger.

In a first aspect, the present invention provides a method
of inhibiting the formation of a cataract in an eye of a
Subject, which comprises administering to the Subject a
pharmaceutical composition comprising an effective cata
ract inhibiting amount of a thioltransferase or thioltrans
ferase derivative. The pharmaceutical composition prefer

contacted with the thioltransferase or derivative thereof.

ferase or derivative thereof.
35

FIG. 10 shows the time dependency of regeneration of
G3PD from HO pretreated rabbit cells by purified recom
DETAILED DESCRIPTION OF THE
INVENTION

also contemplated, Such as thioltransferase derived from E.
coli. In a preferred embodiment, the thioltransferase is
human lens thioltransferase as defined by SEQ ID NO:1.
In the above described methods of inhibiting the forma
tion of cataracts in an eye, the eye may already contain one
or more developing or fully developed cataracts before it is
Accordingly, the above disclosed method can be used to
inhibit the formation of further cataracts in the eye, to inhibit
the progression of any developing cataracts already present
in the eye, or to at least partially reverse the development of
Such mature or developing cataracts in the eye.
Alternatively, the eye may be free of any developing or fully
developed cataracts when it is contacted with the thioltrans

ferase,

FIG. 4 shows the detoxification of bolus HO (0.5 mM)
by rabbit lens epithelial cell line N/N 1003A.
FIG. 5 shows the effect of bolus HO to lens GSH and
protein-thiol mixed disulfide in N/N 1003A cells;
FIG. 6 shows the effect of bolus HO (0.5 mM) on
enzyme activities in N/N1003A cells;
FIG. 7 shows thioltransferase activity in lens epithelial
cells (N/N 1003A) treated with various levels of H.O.
FIG. 8 shows the effect of HO on the growth of rabbit
lens epithelial cells,
FIG. 9 shows the regeneration of G3PD from HO (0.5
mM) pretreated rabbit cells by recombinant human lens

emulsions Such as water/oil emulsions or a triglyceride
emulsion, various types of wetting agents, tablets, enteric
coated tablets and capsules, and So forth.
The thioltransferase may be any naturally occurring
thioltransferase, including, but not limited to mammalian
derived thioltransferases. Exemplary mammalian thioltrans
ferases include, but are not limited to, human, pig, cow, and
rabbit thioltransferases. Also contemplated are tissue spe
cific variants, Such as liver, RBC, placental, and ocular

65

Any Suitable means known to those skilled in the art may
be used to administer the pharmaceutical composition to the
Subject in accordance with the present invention. The com
position may be administered Systemically, or, in a preferred
embodiment, is administered to the eye by directly applying
the composition to the eye.
In another aspect, the present invention provides pharma
ceutical compositions comprising the thioltransferase or
derivatives thereof according to the present invention. Any
Suitable means may be used to administer the pharmaceu
tical compositions to a Subject in accordance with the
present invention. Formulations for the thioltransferase or
derivatives thereof according to the present invention may
be any conventional formulation for protein or peptide
drugs, Such as found in Remington's Pharmaceutical

Sciences, latest edition (Mack Publishing Co.: Easton, Pa.).

Typically, proteins and peptides are administered by
injection, Such as intravenous, intramuscular, Subcutaneous,
or intraperitoneal injection, or using formulations for trans
mucosal or transdermal delivery. These formulations gener
ally include a detergent or penetrant Such as bile Salts,
fusidic acids, and the like. The pharmaceutical composition
may be injected into any part of the Subject's body, including
into one or both of the subject's eyes. These formulations
may also be administered as aerosols or Suppositories. In the
case of transdermal administration, the formulation may be
in the form of a topical ointment, lotion, cream or skin patch,
and may include a transdermal agent. For Systemic
application, the pharmaceutical composition may be applied
to any part of the Subject's body. The compositions accord
ing to the present invention may be adapted for oral
administration, i.e., in the form of tablets, capsules,
Solutions, Suspensions, and other dosage forms adapted for

US 6,379,664 B1
S
oral administration, provided the formulation protects the
thioltransferase or derivatives thereof according to the
present invention from degradation in the digestive System.
Optimization of dosage regimen and formulation is con
ducted as a routine matter and as generally performed in the
art. Although thioltransferase is generally a heat Stable
enzyme, it should be Stored at a cold temperature.
In a preferred embodiment, the eye is contacted directly
with the thioltransferase or derivative thereof. Any suitable
means known to those skilled in the art may be used to
contact the eye with the thioltransferase or derivative
thereof. Examples of Such methods include, but are not
limited to, injection into the eye, or, dropping, Spraying, or
other topical application to the eye. Vehicles for topical
ophthalmic formulations are generally known to those
skilled in the art. Various electrolytes, Solvents, co-Solvents,
Surfactants, preservatives or antimicrobial agents, Viscosity
building agents, etc., are taught in U.S. Pat. No. 5,686,450,
incorporated herein by reference in its entirety.
AS used herein, the term “effective cataract-inhibiting
amount' is intended to encompass any amount which will
inhibit the progression or formation of cataracts in an eye.
The route of administration and the dosage regimen will be
determined by skilled clinicians. AS Such, the effective
cataract-inhibiting amount of the compound will depend on

6
In another embodiment, the administration of thioltrans

ferase or a derivative thereof may comprise Surgically
removing the lens of the eye from the Subject, applying the
thioltransferase or derivative thereof to the lens, and then

Surgically replacing the lens.

In one embodiment of the above described method, the

Subject is a mammal. When the Subject is a mammal, the
Subject may be a human being.
This invention further provides treatment, prevention, or
inhibiting the progression of other eye diseases, including,
but not limited to, glaucoma, macular degeneration, uveitis,

iritis, cornea inflammation (either by injury or disease) or

15

Superoxide (O.), H2O, hydroxyl (OH.) radicals, and Sin
glet oxygen (O.). Reactive oxygen species may be generated
25

various factors known to those skilled in the art, which

include, but are not limited to, the size of the eye, the exact
nature and Severity of the condition being treated Such as the
number and progression of any mature or developing cata
racts already present invention eye, whether the eye is to be
contacted a single time or periodically over a period of time
and the length of such period of time. The period of time
may be any number of days, weeks, months, or years. In one
embodiment, the thioltransferase or derivative thereof is

administered from one to four times per day until the desired

35

results have been achieved. In one embodiment, the effective

cataract-inhibiting amount of the thioltransferase or deriva
tive thereof is an amount that provides a given level of

enzyme activity in the lens. A typical lens (old lens, i.e., 65
years or older) weighs about 200 mg and about 30% of the

weight are proteins. The enzyme activity in a typical old

40

human lens is about 50.6 m Unit or about 1.2x10 Unit

activity per mg lens protein.
For direct administration to the eye, the dosage may be an
amount which provides an enzyme activity of about 1.2x

10 Unit activity per mg lens protein or higher. In another

45

higher than 1.2x10 Unit activity per mg lens protein. In
50

an amount that provides an activity of about 1.2x10 Unit

activity per mg lens protein or higher.
For Systemic administration, the dosage is an amount that

in cells during aerobic cellular metabolism. For example, O.
is converted to Superoxide by oxidative enzymes in the
endoplasmic reticulum, mitochondria, plasma membrane,
peroxisomes, ctyosol, and So forth. Superoxide is converted
to H2O by dismutation and thence to hydroxyl by the
Fe"/Cu" catalyzed Fenton reaction or through the Haber
Weiss reaction. HO is also derived directly from oxidases
in peroxisomes. Reactive oxygen Species may also be ini
tiated within cells by absorption of radiant energy Such as
X-rays, ultraViolet light, or other ionizing radiation. Reactive
oxygen Species may also be produced by reaction of other
free radicals, metabolism of chemicals, drugs, chemothera
puetic agents, pesticides, cigarette Smoke, and fatty foods.
Diseases which may result from oxidative StreSS are
generally known to those skilled in the art, and include, but
are not limited to, rheumatoid arthritis, lupus, Sickle cell
anemia, Sickle cell disease, the effects of aging, lipid per
oxidation of membranes, glycosylation of proteins, oxida
tive modification of proteins, including Sulfhydryl mediated
croSS linking, fragmentation of polypeptide chains, and
enzyme degradation. Oxidative StreSS causes oxidation of
DNA and damages DNA in cells. Such damage may lead to
the formation of tumors. Thus, diseases which result from

embodiment, the dosage may be an amount that provides an
activity of one to Several, or more, orders of magnitude

one embodiment, the dosage may be an amount that pro
vides an activity of about 1.2 Unit activity per mg lens
protein or higher. In another embodiment, the dosage may be

other trauma to the eye. Also, this invention further provides
a method of treating, preventing, or inhibiting the progres
Sion of a disease, in a Subject, resulting from oxidative StreSS
which comprises administering to the Subject a pharmaceu
tical composition comprising an effective oxidative StreSS
inhibiting amount of thioltransferase or derivative thereof.
AS used herein, a disease resulting from oxidative StreSS is
any disease resulting from the effects of reactive oxygen
Species generated in cells. Reactive oxygen Species include

55

provides an activity of 1.2x10 Unit activity per mg lens

oxidative StreSS include diseases which comprise the forma
tion of tumors resulting from oxidative StreSS. Diseases
which comprise the formation of tumors include cancer. For
example, reactions with thymine in DNA produce Single
stranded breaks in DNA. Such DNA damage has been
implicated not only in cell death, but also, in eventual
malignant transformation of cells. Mitochondrial DNA is
also affected by oxidative StreSS.
Other diseases which may result from oxidative stress
include diseases coronary and/or circulatory System, dis

eases of the central nervous system (CNS), inflammatory

protein or higher. In another embodiment, the dosage may be
an amount that provides an activity of one to Several, or

diseases, diseases of the pulmonary System, protein conden

more orders of magnitude higher than 1.2x10 Unit activity

sation diseases, and other diseases. Such diseases include

per mg lens protein. In one embodiment, the dosage may be
an amount that provides an activity of about 1.2 Unit activity
per mg lens protein or higher. In another embodiment, the
dosage may be an amount that provides an activity of about

60

be understood that to achieve the desired level of activity in
the lens, a dose administered Systemically will generally be
higher than a dose administered directly to the eye.

65

1.2x10 Unit activity per mg lens protein or higher. It will

myocardial infarction, Stroke, angina, atherosclerosis,
ischemic disease, reperfusion injury, hypercholsterolemia,
adhesion formation, glaucoma, idiopathic pulmonary
fibrosis, chronic renal failure, nephrolithiasis,
nephrosclerosis, gastric ulcer, cholesterol gallstone disease,
hepatitis, epilepsy and Parkinson's disease, Alzheimer's
disease, asthma, psoriasis, multiple myeloma, and Side
effects of drugs. Such as anticancer drugs, Side effects of
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radiation, and so forth. Thioltransferase or derivatives

Where topical application is used, the composition may be
in the form of a cream or lotion and may include a trans
dermal agent.
In yet another embodiment, a pharmaceutical composition
comprising thioltransferase or a derivative thereof is orally
administered to the Subject. If oral administration is
employed, the composition may be in the form of a capsule,
tablet, Suspension, Solution, and So forth.
When treating any of the above mentioned eye disorders,
an ophthalmic formulation as detailed above may advanta
geously be employed.
In another embodiment, a pharmaceutical composition
comprising thioltransferase or a derivative thereof may be
injected into the Subject. Injection may be intramuscular,
intraperitoneal, intravenous, or Subcutaneous. The pharma
ceutical composition may be injected into any part of the
Subject's body, including the part of the body where oxida
tive StreSS has occurred or is expected to occur, is likely to

thereof may also be for the treatment of diabetes and
complications thereof Such as diabetic cataract, diabetic
retinopathy, neuropathy, nephropathy, and neovasculariza
tion of the cornea or retina.

The compositions comprising thioltransferase or deriva
tives thereof preferably further comprise one or more phar
maceutically acceptable carriers as described above which
includes, but is not limited to, PBS, water, emulsions Such

as oil/water emulsions or triglyceride emulsions, various
types of wetting agents, oral formulations, and So forth. A
pharmaceutically acceptable carrier may be selected taking
into account the desired mode of administration.

Any Suitable means known to those skilled in the art may
be used to administer the pharmaceutical composition to the
Subject in accordance with the present invention. The com
position may be administered Systemically, or, in a preferred

15

embodiment, is administered to the location of oxidative
StreSS.

In another aspect, the present invention provides pharma
ceutical compositions comprising the thioltransferase or
derivatives thereof according to the present invention. Any
Suitable means may be used to administer the pharmaceu
tical compositions to a Subject in accordance with the
present invention. Formulations for the thioltransferase or
derivatives thereof according to the present invention may
be any conventional formulation for protein or peptide
drugs, such as found in Remington's Pharmaceutical Sci

Occur, or may occur.

25

AS used herein, an “effective oxidative StreSS inhibiting
amount' is intended to encompass an amount of thioltrans
ferase or derivative thereof which will inhibit the generation
of reactive oxygen Species in cells. The route of adminis
tration and the dosage regimen will be determined by skilled
clinicians. AS Such, the effective oxidative StreSS inhibiting
amount will depend on various factors known to those
skilled in the art. Such factors include, but are not limited to,

ences (Mack Publishing Co.: Easton, Pa.). Proteins and

the size of the Subject, the mode of administration, the exact
nature and Severity of the condition being treated, whether

Such as intravenous, intramuscular, Subcutaneous, or intra

the thioltransferase or derivative thereof is to be adminis

peptides may advantageously be administered by injection,

peritoneal injection, or using formulations for transmucosal
or transdermal delivery. These formulations generally
include a detergent or penetrant Such as bile Salts, fusidic
acids, and the like. The pharmaceutical composition may be
injected into any part of the Subject's body, including one or
both of the subject's eyes. These formulations may also be
administered as aerosols or Suppositories. In the case of
transdermal administration, the formulation may be in the
form of a topical ointment, lotion, cream or skin patch, and
may include a transdermal agent. For Systemic application,
the pharmaceutical composition may be applied to any part
of the Subject's body. The compositions according to the
present invention maybe adapted for oral administration,
i.e., in the form of tablets, capsules, Solutions, Suspensions,
and other dosage forms adapted for oral administration,
provided the formulation protects the thioltransferase or
derivatives thereof according to the present invention from
degradation in the digestive System. Optimization of dosage
regimen and formulation is conducted as a routine matter
and as generally performed in the art. Although thioltrans
ferase is generally a heat Stable enzyme, it should be Stored
at a cold temperature.
In the above described method of treating or preventing a
disease resulting from oxidative StreSS, any Suitable means
known to those skilled in the art may be used to administer
the thioltransferase or derivative thereof to the subject. In
one embodiment a pharmaceutical composition comprising
thioltransferase or a derivative thereof is administered topi
cally to a part of the subject's body where oxidative stress
is expected to occur, is likely to occur, or may occur. In
another embodiment, a pharmaceutical composition com
prising thioltransferase or a derivative thereof is adminis
tered topically to a part of the Subject's body where oxida
tive StreSS has occurred. It will be recognized, however, that
topical application to one part of a Subject's body can be
expected to have beneficial Systemic effects on other parts.

tered a single time or periodically over a period of time and
the length of such period of time. The period of time may be
any number of days, weeks, months, or years. In one
35

embodiment, the thioltransferase or derivative thereof is

administered from one to four times per day until the desired
results have been achieved. In one embodiment, the effective

40
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oxidative StreSS inhibiting amount of the thioltransferase or
derivative thereof is an amount that provides a given level of
enzyme activity in the affected area.
For direct administration of the compositions according to
the present invention to the affected area, the dosage may be
an amount Sufficient to provide a normal physiological level
of activity or higher. In another embodiment, the dosage is
an amount which provides an activity level which is from
one to Several, or more, orders of magnitude higher than the
normal physiological level of activity. In Still another
embodiment, the dosage is an amount which provides an
activity level which is three or more orders of magnitude
higher than the normal physiological level of activity. In
another embodiment, the dosage is an amount which pro
vides an activity level which is six or more orders of
magnitude higher than the normal physiological level of
activity. In yet another embodiment, the dosage is an amount

which provides an activity of about 1.2x10 Unit activity

per mg protein in the affected area or higher. In another
embodiment, the dosage may be an amount that provides an
activity of one to Several, or more, orders of magnitude

higher than about 1.2x10 Unit activity per mg protein. In

60

one embodiment, the dosage may be an amount that pro
vides an activity of about 1.2 Unit activity per mg protein or
higher. In Still another embodiment, the dosage may be an

amount that provides an activity of about 1.2x10 Unit

65

activity per mg protein or higher.
For Systemic administration, the dosage may be an
amount Sufficient to provide a normal physiological level of
activity or higher in the affected area. In another

US 6,379,664 B1
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embodiment, the dosage is an amount which provides an
activity level which is one to Several, or more, orders of
magnitude higher than the normal physiological level of
activity. In another embodiment, the dosage is an amount
which provides an activity level which is three or more
orders of magnitude higher than the normal physiological
level of activity. In another embodiment, the dosage is an
amount which provides an activity level which is six or more
orders of magnitude higher than the normal physiological
level of activity. In another embodiment, the dosage is an

In Some embodiments of the present invention, the thiol
transferase derivatives may be at least about 75% homolo
gous to the Sequence of a known wild type or native
thioltransferase, including those set forth in SEQ ID
NOS:3-7, or in a preferred embodiment, may be at least
about 75% homologous to the sequence of native HITT set
forth in SEQ ID NO:2. In other embodiments of the present
invention, the thioltransferase derivatives may be at least
about 85% homologous to the Sequence of a known native
thioltransferase, including those set forth in SEQ ID
NOS:3-7, or in a preferred embodiment, may be at least
about 85% homologous to the sequence of native HITT set
forth in SEQ ID NO:2. In yet other embodiments of the
present invention, the thioltransferase derivatives may be at
least about 95% homologous to the sequence of a known
native thioltransferase, including those set forth in SEQ ID
NOS:3-7, or in a preferred embodiment, may be at least
about 95% homologous to the sequence of native HITT set
forth in SEQ ID NO:2. It is also anticipated that certain
non-commonly occurring amino acids may be Substituted
for commonly occurring counterparts to confer desirable
characteristics to the resulting polypeptide.
Furthermore, it is contemplated in Some aspects of the
present invention that thioltransferase derivatives may
encompass polypeptides that comprise only a portion of the
Sequence of thioltransferase, Such as known thioltrans
ferases including those listed in SEQ ID NOS:3-7 and, in a
preferred embodiment, thioltransferase derivatives may
encompass polypeptides that comprise only a portion of the
sequence of HLTT set forth in SEQ ID NO:2. This may be
the case, for example, for a chimeric protein encompassing
active or otherwise desirable portions of a number of pro
teins. A portion may also refer to a truncated polypeptide, be
it Substantially truncated or only slightly truncated. Such
truncated polypeptides may be the result of an idiosyncracy
in the mode of production which results in truncation of
amino acids from a terminal end, or a finding that the
truncated polypeptide has activity similar to or better than
the full-length protein. Preferably, such truncations should
not remove regions critical for biological activity. In a
preferred embodiment, Such truncated polypeptides may
include, for example, truncated proteins containing the three
highly conserved regions as set forth in FIG. 2. It is
contemplated that there may be other critical regions as well,
e.g., regions necessary for inducing proper folding and
proper three-dimensional conformation, catalytic activity,
and the like. The ascertainment of noncritical regions is
readily accomplished by deleting or modifying candidate
regions and conducting an appropriate assay for thioltrans
ferase activity. Regions where modifications result in a loSS
of activity are critical; regions wherein the alteration results
in the same or Similar activity are considered noncritical.
Of course, in Still other aspects of the present invention,
the full length protein, as set forth in SEQ ID NO:2, is
contemplated.
The thioltransferase or derivative thereof according to the
present invention, depending on the pH of its environment,
if Suspended or in Solution, or of its environment when
crystallized or precipitated, if in Solid form, may be in the
form of pharmaceutically acceptable Salts or may be in
neutral form. The free amino groups of the protein are, of
course, capable of forming acid addition Salts with, for
example, inorganic acids, Such as, for example,
hydrochloric, phosphoric, or Sulfuric acid, or with organic
acids Such as, for example, acetic, glycolic, Succinic, man
delic acid, and So forth. The free carboxyl groups are capable
of forming Salts with bases, including inorganic baseS Such

amount which provides an activity of about 1.2x10 Unit

activity per mg protein in the affected area or higher. In
another embodiment, the dosage may be an amount that
provides an activity of one to Several, or more, orders of

magnitude higher than 1.2x10 Unit activity per mg pro

tein. In one embodiment, the dosage may be an amount that
provides an activity of about 1.2 Unit activity per mg protein
or higher. In another embodiment, the dosage may be an
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amount that provides an activity of about 1.2x10 Unit

activity per mg protein or higher. It will be understood that
to achieve the desired level of activity in the affected area,
a dose administered Systemically will generally be higher
than a dose administered directly to the affected area. For
treatment of the eye disease other than cataracts, the dosages
and regimens, formulation, and administration methods
employed may generally be comparable to those detailed

25

above for treatment of cataracts.
In one embodiment of the above described method of

preventing or inhibiting the progression of a disease caused
by oxidative stress, the subject maybe a mammal. When the
Subject is a mammal, the Subject may be a human being.
In one embodiment according to the present invention, the

thioltransferase is human lens thioltransferase (HLTT).
recombinant human thioltransferase (RHLT) according to

35

NOS:3-7.

40

When the thioltransferase is HLTT, the HLTT may be

the amino acid sequence set forth in SEQ ID NO:2.
In an alternative embodiment, the thioltransferase may be
another thioltransferase as described above, including, but
not limited to, the thioltransferases depicted in SEQ ID
In another embodiment, the thioltransferase may be any

isomer or isoenzyme (isozyme) of HLTT or any isomer or

isozyme of thioltransferase from other organisms, including
tissue Specific thioltransferases. Tissue Specific thioltrans
ferases include, but are not limited to, thioltransferases from

45

ocular tissues, RBC, liver, placenta, and So forth.
In another embodiment, the thioltransferase may be a
thioltransferase derivative. Proteins useful as thioltrans

ferase derivatives include proteins or polypeptides having an
amino acid Sequence Substantially homologous to at least a
portion of the amino acid Sequence Set forth in any of amino
acid sequences set forth in SEQ ID NOS:2-7, preferably
SEQ ID NO:2. The term “homologous” refers to the one to
one correlation between the Sequences of two polypeptides.
It will be recognized by those skilled in the art that 100%
homology is not required in all cases and the present
invention is intended to encompass thioltransferase deriva
tives which are Substantially homologous to human lens

50

55

thioltransferase or other thioltransferases. Substantial

homology requires only that the essential nature of the
polypeptide, i.e., folding characteristics and unique features
Such as the active site or other critical regions are preserved.
Thus, modifications of thioltransferase are anticipated and
are within the Scope of the present invention. Such modifi
cations may be deliberate, as through Site directed
mutagenesis, or may be accidental as through mutations in
hosts which are producers of the thioltransferase.

60
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as Sodium, potassium, or calcium hydroxides, and organic
bases, Such as piperidine, glucosamine, trimethylamine,
choline, and caffeine. In addition, the protein may be modi
fied by combination with other biological materials, Such as
lipids and Saccharides, or by Side chain modifications, Such
as acetylation of amino groups, phosphorylation of hydroxy
Side chains, or oxidation of Sulfhydryl groups.
The thioltransferase or derivatives thereof according to
the present invention are preferably purified and isolated. AS
used herein, “purified” and "isolated” are intended to refer
to molecules which have been purified or Synthesized So as
to be Substantially homogeneous. It will be recognized that
the terms do not exclude the possibility that certain impu
rities may be present in the composition So long as the
essential nature of the protein is intact.
In another aspect, the present invention pertains to a DNA
sequence which encodes HLTT, which includes a DNA
Segment that can express the gene encoding HLTT, com
prising the nucleotide sequence of SEQ ID NO:1. Also
contemplated is a DNA sequence which comprises a DNA
Segment analogous to the nucleotide Sequence of SEQ ID
NO:1 wherein analogous DNA segment differs from the
nucleotide sequence of SEQ ID NO:1 wherein one or more
bases are replaced by other bases by means of the degen
eracy of the genetic code without altering the corresponding
amino acid Sequence. Contemplated in yet another embodi
ment are DNA sequences which hybridize with the nucle
otide sequence of SEQ ID NO:1 or a fragment thereof,
wherein Said DNA segment encodes a polypeptide having
thioltransferase activity. In still another embodiment, a DNA
Segment encoding thioltransferase derivatives as defined
above, including homologous amino acid Sequences and
truncated amino acid Sequences.
The present invention also provides a recombinant vector
comprising the above mentioned DNA sequences. In another
embodiment, the present invention provides an expression
vector comprising the above mentioned DNA sequences. AS
is well known, expression Systems are now available com
patible with a wide variety of hosts, including procaryotic
hosts Such as bacteria and eucaryotic hosts Such as yeast,
plant cells, insect cells, mammalian cells, avian cells, and
the like. In Still another embodiment, the present invention
provides transformed cells obtained by introducing into a
host cell a replicable recombinant DNA which comprises a
self-replicable vector and a DNA sequence as set forth in
SEQ ID NO:1 or other DNA sequence as described above.
Transformed host cells may be any host cell which has been
altered to contain an expression System according to the
present invention by any convenient manner of introducing
it, including transfection, Viral infection, electroporation,
and so forth. In a preferred embodiment, the host cell is E.

5

as claimed.
Materials

The following materials were used in the cloning, expres
15

pCR 3.1-Uri vector was purchased from Invitrogen. Primers
for PCR amplification were custom made at Gibco-BRL.

Expression vector pET-23a and its host cell BL2I (DE3)

chased from Pierce.
25

Construction of Human Lens cDNA Library
One hundred human lens capsulotomy Specimens were
obtained from Dr. Joseph Horwitz, Jules Stein Eye Institute,
UCLA. Total RNA was extracted and mRNA was purified
on an oligo dT column. The mRNAs were converted into
cDNAS and the double stranded cDNAS were subcloned into

Uni-ZapTMXR vector using ZAP-cDNA synthesis Kit
35

(Stratagene, La Jolla, Calif., U.S.A.) using EcoR1 and XhoI
1 sites as described in the manual of the provider. The library
was found to have 4x10" plaque forming units per ug
original cl)NA. The background of the library was less than

2%. Two microliters of the library was diluted (1:10) and

used as the template for the PCR as described below.
40

Production of an Initial cDNA Clone by PCR

A21mer Sense (agcatggctcaagcatttgtg, SEQID NO:8) and
a 24mer antisense (gaagaaaaatctgttttgtccccc, SEQ ID NO:9)
primers were designed based on the known nucleotide
45

50

The present invention also provides a proceSS for produc
ing the above described transformant to produce RHLT and
collecting the RHLT from the resultant culture. Any con
ventional means for recovery of the protein may be
employed. For example, the protein produced may be recov
ered from the lysate of the cells if produced intracellularly,
or from the medium if Secreted. Techniques for recovering
recombinant proteins from cell cultures are well understood
in the art, and the proteins can be purified using known
techniques Such as chromatography, gel electrophoresis,
Selective precipitation, and the like.
Human lens thioltransferase can be prepared according to
the method disclosed in Raghavachari et al., “Cloning,

Sion and characterization of human lens thioltransferase.

were obtained from Novagen Inc. T4 Poly nucleotide kinase,
T4 DNA ligase, Taq DNA polymerase restriction enzymes,
and random primer labeling kit were purchased from Gibco
BRL. Reagents for electrophoresis and immunoblots were
purchased from Bio-Rad. Protein assay reagent was pur

coli.

ing a recombinant HLTT (RHLT), which comprises cultur

12
high-level expression, and characterization of human lens
thioltransferase,” Exp. Eye Res., vol. 66, pp. 465–475
(1998), herein incorporated by reference in its entirety. Also
incorporated by reference in its entirety is Lou et al.,
“Thioltransferase is present in the lens epithelial cells as a
highly oxidative StreSS-resistant enzyme, Exp. Eye Res.,
vol. 66, pp. 476-486 (1988). Various examples will be
described below. Such examples Serve to explain the prin
ciples of the invention and are not restrictive of the invention

55
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sequence of pig liver thioltransferase (M31453 GenBank).

The sense primer is phosphorylated by T4 Poly nucleotide
kinase prior to amplification. This phosphorylated primer
was used with the unphosphorylated antisense primer to
generate a 520 bp PCR product phosphorylated on the 5' end
using the template human lens cDNA library and Taq DNA
polymerase. The conditions of the PCR in a reaction volume
of 50 uL were as follows: 40 cycles at 94° C. for 1 min., 57
C. for 1.5 min. and 720° C. for 2 min. The PCR products
were size fractionated on a 2% agarose gel and the band
corresponding to 520 bp was separated and purified using

Qiagen's Gel agarose purification Kit (Vogelstein et al.,

“Preparative and analytical purification of DNA from
agarose,” Proc. Natl. Acad. Sci. U.S.A., vol. 76, 6.15-79
(1979)). This purified PCR product was used for Subsequent
cloning purposes.
Cloning of Lens Thioltransferase into TA3.1 Uni
Vector

65

The purified PCR fragment was cloned downstream of
CMV promoter into TA3.1-Uni using T4DNA ligase at 14
C. for 16 hr and Invitrogen's Top 10F cells were transformed
with the recombinant pCR 3.1 Uni vector based on the

US 6,379,664 B1
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room temperature and the decrease in absorbance at 340 nm
was monitored in a Beckman spectrophotometer. A blank
reaction without the enzyme was monitored simultaneously

13
method of Mead et al., “A universal method for the direct

cloning of PCR amplified nucleic acid,” Bio/techno, vol. 9,

pp.657-63 (1991)). The transformants were selected on LB

plates with 50 lug/ml Kanamycin. The recombinant plasmid
designated as PCR 3.1-HLTT were analyzed by restriction
enzymes HindIII and EcoR1 for the presence of the insert.

as a control blank.

Measurement of Dehydroascorbate Reductase
Activity
Dehydroascorbate reductase activity was measured by the
direct spectrophotometric method of Stahl et al., “A Spec
trophotometric assay for dehydroascorbate reductase, Anal.

Nucleotide Sequence Analysis of the Recombinant
Lens. Thioltransferase

cDNA sequencing of the recombinant thioltransferase
cDNA from both the 5' and 3’ directions were performed on
automated fluorescence DNA sequencer using Thermose

Biochem., vol. 131, 341-44 (1983), based on the change in
absorbance at 265.5 nm as dehydroascorbic acid is reduced

to ascorbic acid. The reaction mixture contained 137 mM

quenase (Amersham) at the Licor-Biotech Inc., Lincoln,
Nebr., U.S.A.

15

Sub Cloning into p.T 23a Vector
PCR 3.1-HLTT was digested with Nhe 1 and EcoR1 at 37

C. for 4 hr in React 4 buffer (Gibco). The HLTT cDNA

the control.

fragment released after restriction enzyme digestion was
Separated on 2% agarose gel, purified and cloned into the
Nhe 1 and EcoR1 sites of p.T 23a expression vector driven

Preparation of Protein Mixed Disulfides-PSSG
and PSSC

by T7 promoter using T4 DNA ligase. BL21 (DE3) cells

were transformed with peT23a-HLTT and the transformants
were selected on LB plates with 50 tug/ml amplicillin. The
resulting positive clones were designated as pET23a-HLTT.

Purified BSA, alpha and gamma crystallins from bovine

25

Expression of HLTT

were added 27.2 mg of 1 mci/ml H-GSH or 17.2 mg/ml
"C-cystine and the samples were maintained at 20° C. for

was added to a final concentration of 0.5 mM and the culture
35

Preparation of Crude Recombinant HLTT
40

induction by centrifugation at 3500 g for 20 minutes and the
pellet was resuspended in 1 ml of 10 mM phosphate buffer

pH 7.4 containing 1 mM dithiothreitol (DTT). 1 mM phenyl
methylsulfonyl fluoride (PMSF), Lysozyme was added to a
45

50

150, 76–85 (1985), with bovine serum albumin as the

Initial specific radioactivities of all the radiolabeled Sub
strates were within the range of 0.25-0.7 Ci/Mol protein.
55

These substrates were incubated at 30° C. with 0.1 M

potassium phosphate buffer pH 7.5, 2 units GSSG reductase,
0.2 mM NADPH, 0.5 mM GSH in the absence or presence
of HLTT. After preincubation at 30° C. for 5 min., reactions
were started by the addition of radiolabeled PSSG or PSSC
60

viously (Raghavachari et al., “Evidence for the presence of
thioltransferase in the lens,” Exp. Eye Res., vol. 63, 433-41

(1996)) with hydroxy ethyl disulfide (HEDS) as substrate.

Briefly the reaction mixture contained 0.2 mM NADPH, 0.5
mM GSH, 0.1 mM Phosphate buffer, 0.4 units GSSG
reductase and an aliquot of the crude cell extract. The
reaction was initiated by the addition of 2 mM HEDS at

disulfides was carried out with purified human lens thiol
transferase by a procedure similar to Mannervik et al., “Role
of cytoplasmic thioltransferase in cellular regulation by
thiol-disulphide interchange,” Biochem. J. vol. 190, pp.

125-30 (1980).

Standard.

Measurement of Thioltransferase Activity
Thioltransferase activity was measured as described pre

ration of radioactivity in the mixed disulfide was determined
simultaneously using the INUS B RAM system. The specific
radioactivity of the synthesized BSA and crystallin-thiol
mixed disulfides were found to be in the range of 0.25-0.7
Ci/Mol protein.
Dethiolation Assay with HLTT

Dethiolation of H or 'C labeled protein-thiol mixed

Protein Determination

Protein content of the crude extract was determined by the
BCA protein assay protocol according to Smith et al.,
“Measurement of protein using BCA.” Anal. Biochem., vol.

1 hr followed by a minimum of 18 hr at -20°C. The samples
were then thawed and dialysed extensively to remove exceSS
GSH, GSSG or cystine in 0.1 M potassium phosphate buffer
pH 7 with 10 mM diethylene triamine penta acetic acid

(DTPA). The purity of the synthesized protein-thiol mixed
disulfides was verified on Superose 12 (gel filtration) col
umn (Pharmacia) using Waters HPLC system. The incorpo

induction.

final concentration of 0.2 mg/ml with Stirring and the cells
were disrupted by Sonication for 3 minutes at 30 second
intervals. The lysed cells were centrifuged to remove the cell
debris and the Supernatant was used for protein analysis,
thioltransferase assay, and Western blot analysis.

corresponding protein-thiol mixed disulfides PSSG and
PSSC based on the procedure of Dickerson et al., “The
culture of rat lenses in high Sugar media: effect on mixed
In brief, to a 4 mg/ml of BSA, alpha and gamma crystallins

medium with 50 tug/ml amplicillin until an ODoo of 0.4–0.6
was reached. At this time isopropylthiogalactoside (IPTG)

Cells were harvested after 0, 2, 4, 6, and 8 hr of IPTG

lens were conjugated to H-GSH and 'C-cystine to form the
disulfide levels,” Curr. Eye Res., vol.14, pp.109-18 (1994).

Transformed BL21 cells were cultured at 37° C. in LB

was continuously incubated for up to 8 hr at 37° C. Equal
number of cells (~1 ml) were removed at various time
intervals (0, 2, 4, 6, 8 hr) to monitor the rate of HLTT

sodium phosphate buffer pH 6.8.1 mM EDTA, 2 mM GSH,
1 mM DHA and various amounts of enzyme in a total
volume of 500 ul. The reaction was initiated by the addition
of DHA and the change in absorbance at 265 nm was
monitored for 5 min. Ablank without any enzyme served as

65

to a final concentration of 2 mM. Reactions were terminated

at various times by the addition of 1 volume of ice cold 20%
TCA followed by centrifugation for 10 min. An aliquot of
the Supernatant was removed and added to 5 ml of bio-safe
liquid Scintillation cocktail and counted in the liquid Scin
tillation counter. Net release of radioactivity in the Super
natant per ml of the reaction mixture was calculated. Thiol
transferase activity is then expressed as mol of PSSG or

US 6,379,664 B1
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PSSC dethiolated per ug thioltransferase protein under the
assay conditions mentioned above.
SDS-PAGE and Immunoblotting Analysis

Isolation, Purification and Cloning of Human Lens

The Laemmeli system (Laemmeli, “Cleavage of structural

Thioltransferase cDNA
5

proteins during the assembly of the head of the bacterioph

age T4,” Nature, vol. 277, pp. 680–88 (1970)) was
was performed as described previously (Blake et al., “A
employed for SDS-PAGE analysis. Immunoblotting analysis
rapid Sensitive method for detection of alkaline phosphate
conjugated antibody on Western blots,” Anal. Biochem., Vol.

136, pp. 175-79 (1984)) in which polyclonal antiserum

raised against PLTT was used as the primary antibody and
alkaline phosphatase conjugated goat anti rabbit IgG color

reaction System (Biorad) was used to detect the positive

15

Signals.

N-terminal Sequence Analysis
An aliquot of the crude recombinant HLTT after induction
with IPTG was separated on 15% SDS-PAGE. The gel was

vectors pCR 3.1 and pET 23a were (a), to obtain large

amounts of the enzyme by over expression in E. coli using

transferred to PVDF (poly vinylidene difluoride) membrane

and stained with amido black. The heavily stained band after
8 hr of IPTG induction corresponding to 11.5 KDa was
sequenced on Procise-494sequencer at the Protein Core
facility of University of Nebraska-Lincoln.
Northern Blot Analysis
Total RNA from bovine Lens, rabbit lens epithelial cells
and pig liver were isolated and purified by the Single Step
method of Chomczynski et al., “A Single Step method of
RNA isolation by acid guanidium thiocyanate phenol

the peT vector and (b), to transfect a mammalian cell line

25

HLTT cDNA Sequence Analysis and Comparisons
with Other Thioltransferases

The nucleotide and the deduced amino acid Sequence of
the coding region of the lens thioltransferase is shown in
FIG. 1. The nucleotides are numbered from 5' to 3' and the

amino acids are numbered from NH to COOH termini. The

(1987). Approximately 10 ug of the total RNA extracted
35

ladder (Gibco-BRL) were electrophoresed on an 11x14 cm

agarose formaldehyde gel. The gel was rinsed in DEPC
water several times, and RNA was transferred to a Nytran

membrane (Schleicher and Sehuell) using the Turboblotter

rapid downward transfer System. The membrane was pre
hybridized and hybridized with human lens thioltransferase

40

cDNA labeled with Pat 65° C. for 1 hr. The membrane was

washed for 15 min at room temperature in 2XSSC solution,
0.1% SDS twice. The final wash at high stringency was

Southern Blot Analysis
DNA from rabbit lens epithelial cell line were extracted
by the method of Gross-Bellard et al., “Isolation of high
molecular weight DNA from mammalian cells,” Eur: J.

50

thioltransferase, J. Biol. Chem., vol.262, pp. 6699-6705

(1987)); Sequence C is human placenta (Padilla et al.,
55

“Purification from placenta, amino acid Sequence, Structure
comparisons, and cDNA cloning of glutaredoxin, Eur: J.

Biochem., vol.227,27–34 (1995)); sequence D is calf thymus
thioltransferase (Klintrot et al., “The primary structure of
60

calf thymus glutaredoxin. Homology with the corresponding
E. coli protein but elongation at both ends with an additional
half-cysteine/cysteine pair, Eur: J. Biochem., vol. 144,

pp.417-23 (1984)); sequence E is rabbit bone marrow
(Hopper et al., “Glutaredoxin from rabbit bone marrow.

electrophoresis of restriction fragments, in Methods in

Enzymology, (Wu, ed., 68, Academic Press: NY, (1979). The

Purification, characterization, and amino acid Sequence
determination by tandem mass spectroscopy,” J. Biol.

filters were hybridized with a 'PdCTP labeled human lens

processed as described earlier in Northern blot analysis and
exposed to X-ray film.

malian Systems and E. coli. Sequence A is the human lens
thioltransferase; Sequence B is pig liver thioltransferase

(Gan et al., “The primary structure of pig liver

hybridization analysis by Southern blotting (Southern, “Gel
thioltransferase cDNA for 1 hr at 65° C. The membrane was

that of the pig liver thioltransferase and has 87% similarity
to that of the human placental glutaredoxin. FIG. 2 repre
Sents the alignment of the deduced amino acid Sequence of
lens thioltransferase to thioltransferases from other mam

Biochemistry, vol. 36, pp. 32–38 (1973). An aliquot of the

genomic DNA was digested with EcoR1, HindIII, Pvull,
Sac1, and fractionated by electrophoresis in 1% agarose
gels. DNA was denatured and transferred to filters for

sequence of the PCR primers used are underlined. The
initiator methionine and the terminator Signal are in bold.
The 520 bp lens cDNA insert possessed a continuous open
reading frame of 318 bp beginning with an ATG initiation
codon and ending with a TAA termination codon followed
by the 3'-noncoding region. The open reading frame encodes
for a polypeptide of 106 amino acids Starting with methion
ine and the predicted molecular weight of the encoded
polypeptide is 11.784 KDal. On comparison with thioltrans
ferases from other tissues using the GCG program, it was
observed that the lens thioltransferase is 98% identical to

45

carried out at 60° C. for 15 min. The membrane was air dried

and exposed to X-ray film for 2 days at -80 C. with
intensifying Screens. To determine the integrity and equal
loading of RNA, duplicate samples along with RNA markers
were ran Simultaneously, Stained with ethidium bromide and
photographed.

using the pCR 3.1 Uni Vector. Restriction enzyme analysis
and DNA sequence analysis clearly Show that we have
Successfully made these recombinant clones which can now
be used for future studies.

chloroform extraction,” Anal. Biochem., vol. 162, 156-59

from bovine lens, rabbit lens epithelial cells, pig liver,
humanplacenta, and 5 lug of 0.24-9.5 kilobase pair RNA

Amplification of HLTT from a pool of humans lens cDNA
by PCR resulted in a single 520 bp fragment. This fragment
was purified and cloned into pCR 3.1 Univector and peT
23a expression vector. The PCR fragment containing the
entire coding Sequence for HLTT was initially cloned into
pCR 3.1 Univector. The recombinant clone was confirmed
for the presence and orientation of the insert by restriction
enzyme analysis with HindIII and EcoR1 and by DNA
Sequencing. To construct the pe.T expression System with
HLTT, pCR 3.1-HLTT was digested with Nhe 1 and EcoR1
to release a 540 bp fragment consisting of the entire coding
Sequence of HLTT and the released fragment was cloned
into Nhe 1 and EcoR1 sites of p.T 23a expression vector.
The resulting positive clones were further confirmed for the
presence of the insert by DNA sequencing.
Our objectives to construct HITT clones in two different

65

Chem., vol. 264, pp. 438-77 (1989); and sequence F is E.
coli thioltransferase (ASlund et al., “Two additional glutare

doxins exist in E. coli glutaredoxin is a hydrogen donor for
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ribonucleotide reductase in a thioredoxin/glutaredoxin 1
double mutant,” Proc. Natl. Acad. Sci. U.S.A., vol. 91, pp.

thioltransferase; -O- is gamma crystallin mixed disulfide;

from the FIGS. 3A and 3B, wherein -- is control

-O- is alpha crystallin mixed disulfide; and -A- is BSA

98.13–17 (1994)). The regions indicated by “*,” “**,” and

***** are, respectively, the active site of the enzyme,
residues in the hydrophobic region, and the GHS binding
site. This alignment is based on the 3D structure of E. coli

mixed disulfide. FIG. 3A shows the dethiolation of alpha,

gamma crystallins and BSA-GSH mixed disulfides (PSSG).

FIG. 3B shows the dethiolation of alpha, gamma crystallins

glutaredoxin (ASlund et al., Supra) using the active site

and BSA-Cystine mixed disulfides (PSSC). Interestingly,

residues and structural elements in that molecule. AS

alpha crystalline-cystine mixed disulfide could not be dethi
olated by lens thioltransferase Gamma crystallin-thiol mixed
disulfide appears to be the favorable substrate for lens

expected, the human lens thioltransferase has identical
amino acid residues in the three highly conserved regions
which are the active site of the enzyme. GSH binding site
and the residues in the hydrophobic region as can be seen
from FIG. 2. Similar to placental thioltransferase human lens
thioltransferase has a cysteine residue in position 8 replacing
serine in other thioltransferase. The only major difference

thioltransferase.

N-terminal Amino Acid Analysis of the Human
Lens. Thioltransferase
15

between the lens thioltransferase and all other thioltrans

The N-terminal amino acid Sequence analysis indicated
the first 10 amino acids of the expressed enzyme to be

ferase is the presence of Valine in position 27 replacing
arginine.

AQEFVNCKIQ (amino acids 2-11 of SEQ ID NO:2) which

Over Expression of HLTT in BL21 Cells
Nhe 1 and EcoR1 fragment of pCR 3.1-HLTT was Sub
cloned into PET 23a expression vector. Positive clones
designated as pET 23a-HLTT were further confirmed for the
presence and orientation of the insert by Sequence analysis.
BL21 cells transformed with pET 23a-HLTT were then
induced by 0.5 mM IPTG for 8 hr. There was a 65-fold
increase in total activity of HLTT over the wild type E. coli

sequence of the protein from the cDNA (FIG.1). Methionine

is in agreement with that of the deduced amino acid

25

after 8 hr of induction in the crude cell extract (data not
shown). The HLTT protein band was also visualized at 11.5

rabbit lens epithelial cell, pig liver, and human placenta (as
positive control) were hybridized to the human lens thiol

KDa on 15% SDS-PAGE with the same cell extracts after

staining with coomassie Blue R-250 (data not shown). This

was verified by immunoblot analysis with anti pig liver
thioltransferase along with the pig liver thioltransferase as
positive control which showed a gradual increase in the
intensity of the 11.5 KDa band, thus confirming the high
level expression of a functionally active HLTT.
In addition, pure recombinant HLTT's intrinsic dehydro
ascorbate reductase activity was found to be 7.8 nmoleS/ug
thioltransferase protein when measured with dehydro ascor
bic acid as the Substrate at 30° C.

Radiolabeled Dethiolation Assays
Alpha and gamma crystallin thiol mixed disulfides were
chosen here as these are the lens proteins likely to form
predominant disulfides with glutathione or cystine under

transferase cDNA labeled with P. The results showed the

presence of a Single positive band with an approximate size

of 0.8 kb (not shown). This also confirmed the sequence
35

40

45

and convenient Substrate for Studying the catalysis of dis
ulfide reduction. BSA-thiol mixed disulfides were used in

comparison to determine the Substrate preference of lens

50

H-PSSG or nmol ''C-PSSC dethiolated per lug of thiol

transferase protein. FIGS. 3A and 3B represent the time
dependent dethiolation of PSSC and PSSC by lens thiol
transferase. It can be seen from the slope of the reaction that
the lens thioltransferase dethiolates gamma crystallin-GSH

mixed disulfide more efficiently (1.15 nmol/ug
thiol transferase), followed by alpha (0.6 nmol/ug
thiol transferase) and BSA-GSH (0.3 nmol/ug
thioltransferase) mixed disulfides. Due to the difference in

the assay System these results were not compared to the
Spectrophotometric assay which measures the loss of
NADPH at 340 nm coupled to GSSG formation while the
radiolabel assay measures the TCA nonprecipitable counts.
The dethiolation of PSSC by lens thioltransferase was

found to be lesser (50-60%) than with PSSG as can be seen

homology of lens thioltransferase to that of liver and pla

cental thioltransferase.

Southern Blot Analysis
Genomic DNA digested with EcoR1, HindIII, Pvul, and
SacI were examined by Southern hybridization using human
lens thioltransferase cDNA as probe. Digestion with EcoR1
and HindIII showed a single positive signal upon hybrid
ization with 'P labeled human lens thioltransferase cDNA.

oxidative StreSS and So can be considered as a well defined

thioltransferase.
The rate of dethiolation was measured in terms of nmol of

which precedes alanine as deduced from the cDNA sequence
was not found at the N terminus of the expressed recombi
nant protein indicating its likely cleavage by the host cell.
The expressed product, Similar to other reports, did not show
any acetyl group at the N-termini.
Northern Blot Analysis
In order to determine the size of the mRNA transcript of
lens thioltransferase, total RNA from bovine lens, pig lens,

55

60
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SacI which has 3 restriction sites resulted in 4 fragments
which hybridized with the HLTT cDNA while PvuII diges
tion resulted in 2 positive signals. These results Suggest that
the thioltransferase gene is a Single copy gene.
The above described cloning and Sequencing of the
human lens thioltransferase is advantageous in that we have
been able to produce large amounts of the enzyme, which
would not otherwise be possible due to the low concentra
tion of the enzyme in the lens and the difficulty in obtaining
the human lens tissue. The recombinant protein that we have
now obtained has been characterized by SDS-PAGE, Immu
noblots and N-terminal amino acid Sequencing and our
results clearly demonstrate the structural similarity of HLTT
to that of thioltransferases from other mammalian Systems.
Southern and Northern hybridizations provide strong evi
dence for the presence of a Single copy gene for thioltrans
ferase and the mRNA transcript size has been found to be
approximately 0.8 kb.
The findings above show the dethiolation of PSSG and
PSSC by lens thioltransferase and its intrinsic dehyrdoascor
bate reductase activity to regenerate ascorbic acid from its
oxidized form indicate that the antioxidant role of thioltrans

ferase is both as a protective agent against oxidation by its
ability to regenerate ascorbic acid and as a repair enzyme by
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EDTA (1X) and gentamicin Solution, glutathione, glu

its dethiolating activity, thus preventing protein aggregation,
an earlier event in cataractogenesis.
The amino acid sequence of HLTT as expected was found
to be similar to a large extent to that of other thioltrans
ferases. This similarity involves all residues previously
known to be highly conserved based on the 3-dimensional

tathione reductase, glutathione Sulfonic acid, cysteic acid

and H2O, were from Sigma Chemical Company (St. Louis,
Mo.). Hydroxyethyl disulfide (HEDS) was purchased from
Aldrich Chemical Company (Milwaukee, Wis.). The BCA
protein assay kit was from Pierce Chemical Company

(Rockford, Ill.). Nylon membrane and nitrocellulose mem
brane were from Schleicher and Schuell (Keene, N.H.).
Ethidium bromide was purchased from Boehringer Man
nheim Corp. (Indianapolis, Ind.). All other chemicals and

Structure of E. coli glutaredoxin or thioltransferase (ASlund
et al., Supra), the active site with 2 half cystine residues
cys-pro-tyr-cys (amino acids 11-14 of SEQ ID NO:7) is
conserved in HLTT similar to other thioltransferases. In

addition, as shown in FIG. 2, there are 2 other highly
conserved areas outside the active Site in all the

thioltransferases, including HLTT. These include the resi
dues thr-Val-pro, representing the hydrophobic Surface area

in E. coli grx and the residues ile-gly-gly-cyS-Ser (amino
acids 80-84 of SEQ ID NOS:4 and 6) or ile-gly-gly-thr-asp
(amino acids 69-73 of SEQID NO:7) representing the GSH
binding site in E. coli. Another interesting observation is the
presence of cysteine in position 8 (a non conserved region)
and 79 (conserved region for human thioltransferases). It has

15

from a four-day-old rabbit (Reddan et al., “Establishment of
epithelial cell lines from individual rabbit lenses,” J. Tissue

Culture Methods, vol. 6, 57–60 (1980); Reddan et al.,

"Retention of lens Specificity in long-term cultures of dip
loid rabbit lens epithelial cells,” Differentiation, vol.33,

168-174 (1986)) and OB3L was from an eight-year-old
rabbit ( Reddan et al., “Establishment and characterization

been Speculated that these 2 residues in conjunction with the
GSH binding site and the site of the enzyme constitute a

of a lens epithelial cell line from an 8-year old rabbit,” Curr.

redox regulatory part of the enzyme (Padilla et al., Supra). AS
Seen in FIG. 2 showing the alignment of amino acid residues
in thioltransferases, all thioltransferases exhibit a high
degree of Similarity, indicating a highly conserved Structure.
The human lens thioltransferase on the whole has 5 cysteine
residues similar to human placental thioltransferase, an

reagents were of analytical grade.
Rabbit Lens Epithelial Cell Culture
Rabbit lens epithelial cell line N/N1003 A was developed

Eye Res., vol. 2,633–639 (1983)). Cells were grown in 5 ml
25

of MEM with 50 tug/ml gentamicin plus 8% rabbit serum

(pH 7.2) in 60x15 mm tissue culture plates in a humidified
atmosphere with 5% CO at 35.5° C. Cells reached 95%

confluence (-2x10 cells) within 3–4 days. They were

divided four to one with fresh medium and Subcultured.

internal methionine and histidine in contrast to human

HO. Treatment of Lens Epithelial Cells in Culture
Rabbit lens epithelial cells were raised to confluence,
trypsinized and plated at 0.8 million in each dish. The cells
were incubated overnight in MEM with 1% rabbit serum and

placental thioltransferase, which does not have these resi
dues and there are no tryptophan residues as reported by

Mieyalet al., Biochemistry, vol. 30, 6088-97 (1991), in the
RBC thioltransferase. Cystine 8 is a replacement of serine in
human lens thioltransferase similar to te report of Padilla et
al., Supra, on human placental thioltransferase. Another
interesting observation is the replacement of arginine with
valine in HITT in position 27 immediately following the

35

active Site.

Also contemplated as within the Scope of the present
invention is the use of an HLTT clone such as the pCR3.1-

40

HLTT clone as described herein transfect mammalian cell

lines, and the cell lines So transfected. Such transfected cell

lines are useful in that they can be used to evaluate the effect
of thioltransferase on lens proteins Subjected to oxidative
StreSS. Also contemplated as within the Scope of the inven
tion are antisense polynucleotides and a method for causing
thioltransferase depletion in a cell by the introduction of an
antisense molecule. Such an antisense molecule may be an
RNA or a single stranded DNA that is complimentary to the
mRNA of the HLTTgene to prevent translation of the HLTT
protein. Such antisense molecules are useful evaluating the
effect of thioltransferase depletion. The creation and com
parison of cell lines which over and under express thiol
transferase would also be useful in providing an excellent
model for the study of the cellular functions of oxidative
StreSS in general, and cataractogenesis in particular.
The following Examples demonstrate that, under oxida
tive StreSS induced by H2O exposure, thioltransferase
shows remarkable resistance to oxidation, while other

defense enzymes, Such as glutathione peroxidase and glu
tathione reductase, exhibit a transient loSS of activity.

45

mM HO was added. Serum-free medium was used to
minimize reaction of peroxide with Serum proteins. At
intervals of 5, 15, 30 min and up to 3 hours, cells in
quadruplicate plates were harvested and used for various

enzymatic assays (TTase, GR, GPX and G-3PD). Free GSH,
total SH and protein-thiol mixed disulfides (PSSG and
PSSC) were determined. HO in the medium was measured
at each time point. A portion of the cells was Saved for a
DNA fragmentation assay. Other cells were photographed
and tested for viability by Trypan Blue staining. Cells were

also exposed to different levels of H2O (0.5-1.0 mM) to
Study the resistance of thioltransferase to HO stress. In
each Study, cells incubated without HO were used as
controls.

50

55

Harvest of Cells and Preparation of Cell
Homogenate
The cells in each plate were harvested by Scraping with a
rubber policeman and the Suspension was centrifuged at
1,700xg for 15 min at 4 C. The pellet was resuspended in
5 ml, 2 mM EDTA, Sonicated to break the cells and

60

centrifuged to collect the Supernatant, which was either used
immediately or stored at -20° C. for biochemical assays.
Protein content in the homogenate was determined using a
Pierce BCA kit, following the method of Smith et al.,
“Measurement of protein using BCA.” Anal. Biochem.,

vol. 150, 76–85 (1985).

Materials

Rabbit lens epithelial cell lines, N/N 1003 A and OB3L
were established in Dr. John Reddan's laboratory at Oakland
University, Rochester, Mich. MEM, rabbit serum, trypsin

then in Serum free MEM for 30 min before a bolus of 0.5

Quantification of Total Thiols, GSH and Protein
65

Thiol Mixed Disulfides

A portion of the cell homogenate was centrifuged and the

Supernatant was immediately used for total thiol assay (GSH

US 6,379,664 B1
21
22
plus Protein thiol) following the method of Ellman, “A during apoptosis,” Proc. Natl. Acad. Sci. U.S.A., vol. 88,
colorimetric method for determining low concentrations of 8485-8490 (1991), and Prigent et al., “A safe and rapid
mercaptains,” Arch. Biochem. BiophyS., vol.74, 443-50 method for analysing apoptosis-induced fragmentation of
(1958). Another portion of the homogenate was treated with DNA extracted from tissues or cultured cells,” J. Immunol.
an equal volume of 20% TCA, centrifuged and the Super 5 Methods, vol. 160, 139-140 (1993). This method is used to
natant was immediately assayed for GSH with Ellman's analyze apoptosis-induced fragmentation of DNA. Approxi
reagent (expressed as nmoles/mg protein). The TCA pre mately 5x10 cells were washed in serum-free medium and
cipitate was used for quantification of PSSG and PSSC centrifuged to collect the cell pellet. DNA was then isolated
following the method of Lou et al., “Protein-thiol mixed and treated with RNase to remove RNAbefore separating by
disulfides in human lens,” Exp. Eye Res., 55,889–96 (1992). agarose
electrophoresis (2%). DNA was stained by
Briefly, the TCA precipitate was washed thoroughly (3x) ethidium gel
bromide
and photographed under UV illumination.
with 10% TCA followed by a wash with ether/methanol
(1/1, V/v) and dried in a dry heating bath (65 C.) overnight.
Effect of HO on the Growth of Lens Epithelial
The dried protein was pulverized and then oxidized with
Cells
performic acid to release non-protein thiols from lens pro 15
teins. The released products of GSH (as glutathione sulfonic
Three rabbit epithelial cell lines N/N 1003A and OB3L
acid), and cysteine (as cysteic acid) were quantified by anion were each seeded at 5x10" per plate containing 5 ml MEM
eXchange amino acid analysis using a DioneX LC System plus 1% rabbit serum. Cells cultured in MEM with 1% rabbit
(Sunnyvale, Calif.). Values were expressed as nmoles/mg Serum remain viable but do not grow. Three plates from each
dry weight.
line were counted 20 hours later to Verify the Starting count.
Cells from the remaining plates were cultured for 30 minutes
Enzyme ASSays of the Cell Homogenate
In each enzyme assay, reaction mixtures without the cell in Serum-free MEM and then in medium containing a single
homogenate were used as blanks. The activity of each dose of 0.05 mM HO. After 3 hrs, the medium was
enzyme was expressed as miniumit (mu)/mg protein. Thiol replaced with MEM containing 8% rabbit serum. The
transferase was assayed following the method of Mieyal et 25 Serum-containing medium was replaced on days three and
al., Supra, as modified by Raghavachari et al., “Evidence for Six and cells were counted on day Seven using a Coulter
Counter (Miami, Fla.).
the presence of thioltransferase in the lens,” Exp. Eye Res.,
vol. 63, 433-41 (1996). The reaction was carried out in the
Effect of a Single Bolus of HO on Lens Cells
presence of NADPH, GSH and GR with the synthetic
disulfide, hydroxyethyl disulfide (HEDS), as substrate. The
A single dose of H2O (0.5 mM) in the medium was
decreased O.D., for NADPH was monitored for enzyme degraded quite rapidly when incubated in the presence of
activity. GPx was assayed following the method described 800,000 lens epithelial cells. FIG. 4 depicts the detoxifica
by Spector et al., “The prevention of cataract caused by tion of bolus HO (0.5 mM) by rabbit lens epithelial cell
oxidative stress in cultured rat lenses. I.H2O and photo line N/N1003A in the absence of lens cells (-O-) and in the
chemically induced cataract,” Curr. Eye ReS., Vol.12, 35 presence of lens cells (--). The level of HO in the
163-179 (1993), based on the decreased absorption at 366 medium decreased with time. Half of the HO was detoxi
nm as the result of GPx catalyzed oxidation of NADPH by fied after 30 min and it was completely dissipated within 120
substrate H.O. GSH and GR were added as cofactors. The min. In contrast, the level of HO remained constant when
GR assay was performed following the method of Straatsma added to MEM and incubated without cells. The morphol
et al., "Lens capsule and epithelium in age-related cataract,” 40 ogy of the H-O-treated N/N1003A cells was identical to
Am. J. Ophthalmol., vol. 112,283-96(1991), using GSSG as controls during the 3 hr exposure. Trypan Blue Staining
substrate. The decreased absorbance (340 nm) with NADPH confirmed that the cells exhibited little or no cell death (data
consumption was monitored for GR activity. G-3PD activity not shown). DNA fragmentation assay (data not shown)
was determined using the method of Byers, showed that these cells exhibited no DNA damage, strongly
“Glyceraldehyde-3-phosphate dehydrogenase from yeast,” 45 confirming the absence of apoptosis.
Methods Enzymol., vol.89, 327–35 (1982), modified by
Spector et al. (1993), Supra. The reaction was initiated by
Effect of Bolus HO. Treatment on Lens SH and
Protein-Thiol Mixed Disulfides
addition of glyceraldehyde-3-phosphate and the change in
absorbance at 340 nm between 20-50 second was used to
Following treatment with 0.5 mM HO the cellular GSH
determine G-3PD activity.
50 level dropped 60% from 68.7+14.9 nmoles/mg protein
within five min and stayed at this level before it began to
H.O. Measurement in the Culture Medium
The concentration of H2O, was measured using a colo increase at 90 min and recovered to nearly 100% of normal
rimetric method of Hildebrandt et al., “Hydrogen peroxide by two hrs (FIG. 5). FIG. 5 shows the effect of bolus HO
in hepatic microsomes,” Meth. Enzymol, vol. LII, 342-350 to lens GSH and protein-thiol mixed disulfide in N/N 1003A
(1978), modified by Spector et al. (1993), supra. An aliquot 55 cells wherein GSH level is represented by -O-, PSSG level,
of the medium (50 uL) was mixed thoroughly with 950 uL measured as GSO3H, is represented by --, PSSC level,
of autoclaved, double-distilled water containing 50 till of measured as CSO3H, is represented by -O-. The initial GSH
50% TCA, followed by mixing with 50 uL of 30 mM concentration was 68.7+14.9 nmoles/mg; PSSG was
ferroammonium sulfate and 50 uL of 2.5 M KSCN. The 60 0.19+0.02 nmoles/mg dry wt (n=4); PSSC was 0.07+0.01
absorbance was read at 480 nm after Standing at room nmoles/mg dry wt. The total SH groups (GSH plus protein
temperature for 10-15 min. A standard curve of HO, with SH) showed a similar pattern to free GSH in response to
HO (data not shown). In contrast to the decrease in GSH,
known concentrations was generated for calculation.
protein-thiol mixed disulfides were greatly increased. AS
Assay for DNA Fragmentations in the Epithelial
shown in FIG. 5, PSSG was elevated 6.5 fold over the basal
Cells
65 level of 0.07+0.01 nmoles/mg dry wt and reached a plateau
DNA fragmentation analyses followed the procedures of within 15 minutes. The increase in protein-thiol mixed
Hogquist et al., “Interleukin which is processed and released disulfides was inversely related to the level of GSH in the
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cells. The level of protein-thiol mixed disulfides began to
decline only after the level of free GSH increased. At this
time H2O in the medium was almost completely detoxified

3.6 fold increase in number. These results are Summarized in

the inoculum. Cells from line OB3L increased to 180,000, a

FIG.8 wherein Orepresents the starting count, O represents

(90 min). The PSSG level continued to decrease at intervals the control, and X represents the HO treated cells.
beyond 60 min (see FIG. 5). Similar to PSSG but in much 5 Rabbit lens epithelial cell line N/N1003A was chosen
Smaller scale, the level of PSSC also peaked (2-fold increase Since it has a high level of antioxidant enzymes (Giblin et al.,
from a basal level of 0.19+0.02 nmoles/mg dry wt) 30 min “Detoxification of HO, by cultured rabbit lens epithelial
after HO was added and then decreased to the basal level cells: Participation of the glutathione redox cycle, Exp. Eye
at 90 min.
Res., vol. 40, 827–40 (1985); Giblin et al., “The relative
1O roles of the glutathione redox cycle and catalase in the
Effect of a Bolus of HO on Enzymes in Lens
detoxification of HO, by cultured rabbit lens epithelial
Epithelial Cells
cells,” Exp. Eye Res., vol. 50,795–804 (1990)). This study
Since this study is focused on the response of thioltrans
ferase to H2O, it was considered important to compare the
effect of HO on the activity of thioltransferase with its
effect on other enzymes. FIG. 6 shows the effect of bolus

HO (0.5 mM) on enzyme activities in N/N1003A cells

wherein -O- represents thioltransferase; -O- represents
glycero-3-phosphate dehydrogenase; -- represents glu

tathione peroxidase; and -O- represents glutathione reduc

tase. The initial thioltransferase activity was 16.0+5.6

mU/mg (n=24); G-3PD was 167+5.5 mU/mg (n=4); GPx
was 19.1+4.3 mu/mg (n=4); GR was 26.4+1.8 mU/mg (n8).
The data is expressed as mean+S.D. As shown in FIG. 6,
glycero-3-phosphate dehydrogenase (G-3PD) was the most
sensitive to H2O of the enzymes tested. It lost 95% of its
activity from the initial value of 167+5.5 m U/mg within 5
min of H2O treatment. The activity was regained quickly
when HO began to diminish in the medium. When

HO was no longer present in the medium (120 min),

G-3PD regained 40% of its activity and recovered up to 60%
of the activity after 180 min. A less severe and delayed

inhibition was observed in the activity of both GPx (60%
maxima loss at 60 min from 19.1+4.3 mU/mg) and GR (30%
maxima loss at 90 min from 26.4+1.8 mU/mg). In marked
contrast, thioltransferase activity remained constant during
the entire experiment (at 16+5.6 mU/mg, see FIG. 6). Only
when a higher dose of H2O (0.8-1.0 mM) was used, did
thioltransferase show a brief loss in activity (<30% maxi
mum at 60 min) and a Swift recovery (FIG. 7). FIG. 7 shows
thioltransferase activity in lens epithelial cells (N/N 1003A)
treated with various HO levels wherein -A- represents 0.5
mM HO2; -O- represents 0.8 mM H.O.; and -O- repre
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focused on thioltransferase, an enzyme that has not been
previously studied in cultured lens epithelial cells. The
protocol for the present Study of oxidative-StreSS induced by
a bolus of HO was similar to that of Giblin et al., 1990,
Supra. The rate of H2O2 dissipation in this study agrees with

the earlier report (Giblin et al., 1990, Supra). HO in the

medium was removed very efficiently by the lens cells from
the two rabbit cell lines, indicating that these cells can
defend themselves against this level of oxidative insult.
Cells from line N/N1003A subjected to a bolus of HO
exhibited a normal morphology without visible DNA frag
mentation. The fact that there was no DNA fragmentation is
consistent with the viability and growth data and indicates
that the cells exposed to H2O2 did not undergo apoptosis. It
should be noted however, that HO does induce Single
strand breaks in DNA following exposure of lens epithelial

cells to H2O (Spector et al., “Repair of H-O-induced DNA
damage in bovine lens epithelial cell cultures,” Exp. Eye

Res., vol. 49,685-698 (1989); Reddan et al., “The superox
ide dismutase mimic TEMPOL protects cultured rabbit lens
epithelial cells from hydrogen peroxide insult, Exp. Eye
Res., vol.56,543–554 (1993)). N/N1003A showed a stronger
resistance to HO induced mitotic inhibition (see FIG. 8)

compared to cells from the other cell line, OB3L. One of the
factors that may contribute to the increased Susceptibility of
line OB3L to H2O insult is that these cells have a lower

level of GR than line N/N1003A (Reddan et al., “Influence

of the activity of glutathione reductase on the response of
cultured lens epithelial cells from young and old rabbits to
hydrogen peroxide,” Exp. Eye Res., vol. 45, 209-221

(1988)).

The redox status of the cells changed with the amount of
sents 1.0 mM HO. The initial thioltransferase activity was 45 HO
present in the medium. At the initial burst of oxidation,
16.0+5.6 mU/mg (n=24).
GSH immediately decreased, likely due to its Swift usage for
One other line of rabbit lens epithelial cells was tested for
defense enzymes to combat the StreSS. The oxidized
its response to HO. OB3L, which originated from an various
GSH quickly formed protein-GSH mixed disulfide, as can
eight-year old rabbit, showed Similar pattern in be
seen in FIG. 5 where a mirror image of these two
thioltransferase, GSH and G-3PD activity as line N/N1003A 50 parameters
is shown. The total thiols in the cells also
(FIG. 6) after HO treatment (data not shown).
decreased during this period, reflecting the general change in
the redox Status, i.e., Sulfhydryl groups in GSH and proteins
Effect of HO on the Growth of Rabbit Lens
were oxidized with the concomitant formation of protein
Epithelial Cells
thiol mixed disulfides. GSH levels began to recover as HO
Since proliferation is a sensitive indicator of oxidative 55 in the medium diminished. Moreover, as the intracellular
damage we examined the effect of a single dose of 0.05 mM level of GSH increased, the accumulated PSSG in the cell
HO on the growth of 50,000 cells from each of the cell decreased. This finding agrees with the lens organ culture
lines. Controls were not treated with H.O. Cells (50,000) in studies where elevated PSSG was spontaneously dethiolated
serum-free MEM were exposed to 0.05 mM HO. Three over a period of time after the H2O exposed lens was
hours after HO addition, cells were cultured in MEM 60 cultured in peroxide-free medium (Cuiet al., “The effect and
containing 8% rabbit Serum, a medium known to foster cell recovery of long term HO exposure on lens morphology
proliferation. Cells were counted 7 days after HO treat and biochemistry.” Exp. Eye. Res., vol. 57, 157-167 (1993);
ment. The cells that were not exposed to H2O, increased to Lou et al., “Recovery of oxidative damage in human lenses,”
2-2.5 million cells in seven days. The susceptibility of the Invest. Ophthalmol. Vis. Sci. vol. 35 (Suppl.), 1569 (1994);
two cell lines to HO-induced growth inhibition varied. 65 Lou et al., “Further Studies on the dynamic changes of
Cell line N/N 1003A was more resistant to oxidation and
glutathione and protein-thiol mixed disulfides in H2O2
grew from 50,000 to 830,000 cells, a 16-fold increase over induced cataract in rat lenses: distributions and effect of
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aging, Curr. Eye Res., vol. 14.951-958 (1995); Wang et al.,

26
thioltransferase can dethiolate PSSG and PSSC (more pref
erence to PSSG), similar to thioltransferase in red blood
cells (Gravina et al., “Thioltransferase is a specific glutathio

“Relationship of protein-glutathione mixed disulfide and
thioltransferase in H-O-induced cataract in cultured pig

lens,” Exp Eye Res., vol. 64, 693–700 (1997)). In the organ

nyl mixed disulfide oxidoreductase,” Biochemistry, vol. 32,

culture Study, we speculated that an enzyme must be present
in the lens to dethiolate the glutathione thiolated protein

3368–3376 (1993)). It is likely that the defense enzymes

recent discovery of the dethiolating enzyme,
thioltransferase, in the lens and the presence of mRNA in the

in the cells were all thiolated and inactivated (through SH
groups in these enzymes) under the oxidative-stress induced
by HO. Thioltransferase, being resistant to oxidation, with

such as GR, GPx and the energy providing enzyme G-3PD

(PSSG). This may also apply to the lens epithelial cells. Our

the help of adequate levels of cellular GSH and GR, may
thus function as a rescuer by dethiolating the inactivated
enzymes and restoring their activity. The following Example
was performed to determine the role of thioltransferase in
restoring G3PD activity after oxidative stress.

cultured lens epithelial cells (Wu et al., Distribution of

thioltransferase in ocular tissues.” Invest. Ophthalmol. Vis.
Sci., vol. 39, 476-80 (1998)) strongly supports such a
hypothesis.
Of all the enzymes tested in this study thioltransferase
was the only one whose activity was not adversely affected
by H2O2. This oxidative StreSS-resistant nature was uniform
in both rabbit lens cell lines. Thioltransferase activity was
only slightly reduced when cells from line N/N1003A were

15

Regeneration of G3PD from Rabbit Epithelium
Cell Culture after Oxidative Stress

1.6 million of rabbit epithelium cells were exposed to 0.5
mM HO for 15 minutes. The cells were resuspensed in 2
ml of EDTA pH 8.0 and broken by Sonication. After
centrifugation, the Supernatant was desalted with PD-10
column which equilibrated and eluted with 2 mM EDTA.

exposed to a bolus of 0.8-1.0 mM H.O. (FIG. 7). G-3PD

was extremely Sensitive to oxidation, which agrees with the
observation of Jedziniak, “Photo-oxidative damage to len
ticular GAPDH and its relationship to aldehyde

metabolism.” Exp. Eye Res., vol. 50, 589–596 (1990). The

phenomenon of a near-total loSS in activity at the onset of
H2O insult and a slow recovery in activity of this enzyme
was noted in the present Study. Two known oxidation
defense enzymes, GR and GPX showed a substantial loss of
activity before they were restored.
Axelsson et al., “An essential role of cytosolic thioltrans
ferase in protection of pyruvate kinase form rabbit liver
against oxidative inactivation,” FEBS Lett., vol., 152,

114-118 (1983), reported the protective role of thioltrans
ferase against an inactivated pyruvate kinase by oxidative
stress in rabbit liver. G-3PD, a thiol-dependent enzyme may
also preserve its activity against oxidation by thioltrans
ferase and GSH in human lung carcinoma cells (Brodie et
al., “Cellular recovery of glyceraldehyde-3-phosphate dehy
drogenase activity and thiol Status after exposure to
hydroperoxides,” Arch. Biochem. BiophyS., vol. 276,
212-218 (1990)). The high oxidation-resistant nature of
thioltransferase, coupled with its Suggested mechanism of
action (Terada et al., “Study on human erythrocyte thiol
transferase: Comparative characterization with bovine
enzyme and its physiological role under oxidative StreSS, J.
Biochem., vol. 111, 688–692 (1992); Starke et al., “Sensi
tivity of protein Sulfhydryl repair enzymes to oxidative
stress,” Free Radical. Biol. S. Med., vol. 23, 373-384

(1997)) makes it a candidate responsible for repairing the

damage induced by oxidative StreSS. AS Shown above, lens

The elute with G3PD was collected and concentrated with
25

centriprep 3 into about 1 ml for the following regeneration.
100 till of the above sample was incubated with 0.3 mM

NADPH, 1 mM GSH, (stock solutions 2 mM NADPH in 50

mM triethanolamine, pH 7.5 and 5 mM GSH in 50 mM

triethanolamine, ph 7.5), 3 U GR/ml and about 0.3 U of
recombinant human lens thioltransferase (RHLT) in a total
volume of 0.2 ml at 25° C. for 0–60 min. G3PD activity
35

regenerated by GSH recycling system with and without
thioltransferase was represented as the percentage of G3PD
activity regenerated by 30 mM DTT. The results are shown
in FIG. 9. The time dependency of regeneration of G3PD
from H2O (0.5 mM) pretreated rabbit cell by purified
recombinant human lens thioltransferase is shown in FIG.
10.

40

The description above should not be construed as limiting
the Scope of the invention, but as merely providing illustra
tions to some of the presently preferred embodiments of this
invention. In light of the above description and examples,
various other modifications and variations will now become

45

apparent to those skilled in the art without departing from
the Spirit and Scope of the present invention as defined by the
appended claims. Accordingly, the Scope of the invention
should be determined Solely by the appended claims and
their legal equivalents. All references cited herein are hereby
incorporated by reference in their entireties.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 9
<210> SEQ ID NO 1
&2 11s LENGTH 522
&212> TYPE DNA

<213> ORGANISM: Homo sapiens
&22O > FEATURE

<221 NAME/KEY: CDS
<222> LOCATION: (4) . . (324.)
<400

SEQUENCE: 1

gcc atg gct caa gag titt gtgaac toc aaa atc cag cot gog aag gtg

48
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-continued

Met Ala Glin Glu Phe Val Asn Cys Lys Ile Gln Pro Gly Lys Val
1

5

10

15

gta gtt titc atc aag ccc acc toc coc titc toc gta aag aca cag gag

96

Val Val Phe Ile Lys Pro Thr Cys Pro Phe Cys Val Lys Thr Glin Glu
2O

25

30

citc ctic agc caa ttg ccc titc aaa gaa ggg citt citg gaa titt gtc gat

144

Leu Lleu Ser Glin Leu Pro Phe Lys Glu Gly Lieu Lleu Glu Phe Val Asp
35

40

45

att aca gcc acc agt gac acc aac gag att caa gat tat citg caa cag

192

Ile Thr Ala Thr Ser Asp Thr Asn Glu Ile Glin Asp Tyr Leu Gln Glin
5O

55

60

citc aca gga gCC aga acg gta colt c.gg gtc titt atc ggit aaa gag tot

240

Leu Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Glu Cys
65

70

75

ata ggt gga toc act gat cita gala agt at g cac aag aga ggg gag citc

288

Ile Gly Gly Cys Thr Asp Leu Glu Ser Met His Lys Arg Gly Glu Lieu
8O

85

90

95

ttg acc cgc citg cag caa att gga gct citg aaa taa ttacagcaga

334

Lieu. Thir Arg Lieu Glin Glin Ile Gly Ala Lieu Lys
1 OO

105

gcag accolaa gotgatagot coctitgagag citggatggca gtgcagataa togacagogct

394

to citggtgga tiggatgcc.gg gctacct tca citcagotgca act actottt acttaaaaat

454

totgaaatgt gttaa.cccaa ataattgggg ggagtgg gtt ttgggggaca aaacagattit

514

ttcttctg

522

<210> SEQ ID NO 2
&211's LENGTH 106
&212> TYPE PRT

<213> ORGANISM: Homo sapiens
<400

SEQUENCE: 2

Met Ala Glin Glu Phe Val Asn Cys Lys Ile Gln Pro Gly Lys Val Val
1

5

10

15

Val Phe Ile Llys Pro Thr Cys Pro Phe Cys Val Lys Thr Glin Glu Leu
2O

25

30

Leu Ser Glin Leu Pro Phe Lys Glu Gly Lieu Lieu Glu Phe Wall Asp Ile
35

40

45

Thr Ala Thir Ser Asp Thr Asn. Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu
5O

55

60

Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Glu Cys Ile
65

70

75

8O

Gly Gly Cys Thr Asp Leu Glu Ser Met His Lys Arg Gly Glu Lieu Lieu
85

90

95

Thr Arg Lieu Glin Glin Ile Gly Ala Lieu Lys
100

105

<210> SEQ ID NO 3
&2 11s LENGTH 106
&212> TYPE PRT
<213> ORGANISM: Sus scrofa

<400

SEQUENCE: 3

Met Ala Glin Ala Phe Val Asn Ser Lys Ile Gln Pro Gly Lys Val Val
1

5

10

15

Val Phe Ile Llys Pro Thr Cys Pro Phe Cys Arg Lys Thr Glin Glu Leu
2O

25

30

Leu Ser Glin Leu Pro Phe Lys Glu Gly Lieu Lieu Glu Phe Wall Asp Ile
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30
-continued

35

40

45

Thr Ala Thir Ser Asp Thr Asn. Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu
5O

55

60

Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Glu Cys Ile
65

70

75

8O

Gly Gly Cys Thr Asp Leu Glu Ser Met His Lys Arg Gly Glu Lieu Lieu
85

90

95

Thr Arg Lieu Glin Glin Ile Gly Ala Lieu Lys
100

105

<210> SEQ ID NO 4
&2 11s LENGTH 106
&212> TYPE PRT

<213> ORGANISM: Homo sapiens
<400

SEQUENCE: 4

Met Ala Glin Glu Phe Val Asn Cys Lys Ile Gln Pro Gly Lys Val Val
1

5

10

15

Val Phe Ile Llys Pro Thr Cys Pro Tyr Cys Arg Arg Ala Glin Glu Ile
2O

25

30

Leu Ser Glin Leu Pro Ile Lys Glin Gly Lieu Lieu Glu Phe Wall Asp Ile
35

40

45

Thr Ala Thr Asn His Thr Asn. Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu
5O

55

60

Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Asp Cys Ile
65

70

75

8O

Gly Gly Cys Ser Asp Leu Val Ser Leu Glin Gln Ser Gly Glu Leu Leu
85

90

95

Thr Arg Lieu Lys Glin Ile Gly Ala Leu Glin
100

<210

105

SEQ ID NO 5

&2 11s LENGTH 105
&212> TYPE PRT
<213> ORGANISM Bos taurus

<400

SEQUENCE: 5

Met Ala Glin Ala Phe Val Asn Ser Lys Ile Gln Pro Gly Lys Val Val
1

5

10

15

Val Phe Ile Llys Pro Thr Cys Pro Tyr Cys Arg Lys Thr Glin Glu Leu
2O

25

30

Leu Ser Glin Leu Pro Phe Lys Glin Leu Lieu Glu Phe Val Asp Ile Thr
35

40

45

Ala Ala Gly Asn. Ile Ser Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu. Thr
5O

55

60

Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Glin Glu Cys Ile Gly
65

70

75

8O

Gly Cys Thr Asp Leu Val Asn Met His Glu Arg Gly Glu Lieu Lieu. Thr
85

90

Arg Lieu Lys Glin Met Gly Ala Leu Glin
100

105

<210> SEQ ID NO 6
&2 11s LENGTH 107
&212> TYPE PRT

<213> ORGANISM: Oryctolagus cuniculus
<400

SEQUENCE: 6

95
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-continued
Met Ala Glin Glu Phe Val Asn Ser Lys Ile Gln Pro Gly Lys Val Val
1

5

10

15

Val Phe Ile Llys Pro Thr Cys Pro Tyr Cys Arg Lys Thr Glin Glu Ile
2O

25

30

Leu Ser Glin Leu Pro Phe Lys Glin Gly Lieu Lieu Glu Phe Wall Asp Ile
35

40

45

Thr Ala Thr Ser Asp Met Ser Glu Ile Glin Asp Tyr Leu Gln Glin Leu
5O

55

60

Thr Gly Ala Arg Thr Val Pro Arg Val Phe Leu Gly Lys Asp Cys Ile
65

70

75

8O

Gly Gly Cys Ser Asp Lieu. Ile Ala Met Glin Glu Lys Gly Glu Lieu Lieu
85

90

95

Ala Arg Lieu Lys Glu Met Gly Ala Lieu Arg Glin
100

<210

105

SEQ ID NO 7

&2 11s LENGTH 85
&212> TYPE PRT

<213> ORGANISM: Escherichia coli

<400

SEQUENCE: 7

Met Glin Thr Val Ile Phe Gly Arg Ser Gly Cys Pro Tyr Cys Val Arg
1

5

10

15

Ala Lys Asp Leu Ala Glu Lys Lieu Ser Asn. Glu Arg Asp Asp Phe Glin
2O

25

30

Tyr Glin Tyr Val Asp Ile Arg Ala Glu Gly Ile Thr Lys Glu Asp Lieu
35

40

45

Gln Glin Lys Ala Gly Lys Pro Val Glu Thr Val Pro Glin Ile Phe Val
5O

55

60

Asp Glin Gln His Ile Gly Gly Tyr Thr Asp Phe Ala Ala Trp Wall Lys
65

70

75

8O

Glu Asn Lieu. Asp Ala
85

<210

SEQ ID NO 8

<211& LENGTH 21
&212> TYPE DNA
<213> ORGANISM: Sus scrofa

<400

SEQUENCE: 8

agcatggctc. aag catttgt g

21

SEQ ID NO 9
LENGTH
TYPE

24
DNA

ORGANISM: Sus scrofa

<400

SEQUENCE: 9

gaagaaaaat citgttttgtc. ccc.c

What is claimed is:

1. A method of inhibiting the formation of a cataract in an
eye, which comprises contacting the eye with an effective
cataract-inhibiting amount of a human lens thioltransferase
(HLTT).
2. The method according to claim 1, wherein Said human
lens thioltransferase is an expression product of a trans
formed host cell comprising a DNA molecule coding for
HLTT.

24

60

65

3. The method according to claim 1, wherein the eye
contains a developing or fully developed cataract.
4. The method according to claim 1, wherein the eye does
not contain a developing or fully developed cataract.
5. A method of inhibiting the formation of a cataract in an
eye, which comprises administering to the Subject a phar
maceutical composition which comprises an effective
cataract-inhibiting amount of a human lens thioltransferase.
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6. The method according to claim 5, wherein said human
lens thioltransferase is an expression product of a trans
formed host cell comprising a DNA molecule coding for

17. The method according to claim 16, wherein said
human lens thioltransferase is an expression product of a
transformed host cell comprising a DNA molecule coding

HLTT.

for HLTT.

7. The method according to claim 5, wherein the eye
contains a developing or fully developed cataract.
8. The method according to claim 5, wherein the eye does
not contain a developing or fully developed cataract.
9. The method according to claim 5, wherein the subject
is a mammal.

10. The method according to claim 9, wherein the subject
is a human.

11. The method according to claim 5, wherein adminis
tering the pharmaceutical composition to the Subject com
prises applying the pharmaceutical composition to the eye of
the Subject.
12. A method of inhibiting the progression of cataract
formation in an eye of a Subject which comprises adminis
tering to the Subject a pharmaceutical composition which
comprises an effective cataract-inhibiting amount of a

15

transferase.

22. The method according to claim 21, wherein Said
human lens thioltransferase is an expression product of a
transformed host cell comprising a DNA molecule coding

human lens thioltransferase.

13. The method according to claim 12, wherein said
human lens thioltransferase is an expression product of a
transformed host cell comprising a DNA molecule coding
for HLTT.

14. The method according to claim 12, wherein the eye
contains a developing or fully developed cataract.
15. The method according to claim 12, wherein the eye
does not contain a developing or fully developed cataract.
16. A method of inhibiting the progression of cataract
formation in an eye which comprises contacting the eye with
an effective cataract-inhibiting amount of a human lens
thioltransferase.

18. The method according to claim 16, wherein the eye
contains a developing or fully developed cataract.
19. The method according to claim 16, wherein the eye
does not contain a developing or fully developed cataract.
20. The method according to claim 12, wherein admin
istering the pharmaceutical composition to the Subject com
prises applying the pharmaceutical composition to the eye of
the Subject.
21. A method of delaying the onset of cataract formation
in an eye of a Subject which comprises administering to the
Subject a pharmaceutical composition which comprises an
effective cataract-inhibiting amount of a human lens thiol

for HLTT.
25

23. A method of treating a cataract in an eye of a Subject
which comprises administering to the Subject a pharmaceu
tical composition which comprises an effective cataract
inhibiting amount of a human lens thioltransferase.
24. The method according to claim 23, wherein said
human lens thioltransferase is an expression product of a
transformed host cell comprising a DNA molecule coding
for HLTT.
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